Obi Pharma R&D Director Chen Ya-chi appointed acting CEO to accelerate new drug development
NQ Score
0/100
N1 Content Completeness
5
AI Summary (NQ-processed)
Taiwan Bio-development (Obi Pharma) announced that its current Head of R&D, Dr. Chen Ya-chi, has been appointed as acting CEO following the retirement of CEO Wang Hui-chun. Dr. Chen will leverage her 20 years of international pharmaceutical company experience to accelerate Obi Pharma's new drug development and international market launch schedule.